All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Catherine ThieblemontScientific Advisory Board Member
Professor Catherine Thieblemont is the Head of the Hemato-Oncology Department at Hôpital Saint-Louis, Paris, FR. Her expertise lies in chronic lymphoproliferative syndromes, such as Hodgkin and non-Hodgkin lymphoma and chronic lymphocytic leukemia. As the Head of the Hemato-Oncology Department, she contributes to clinical research, including the evaluation of clinical activity in phase II and III trials, as well collaborating with the Center for Clinical Investigations to oversee phase I trials.
Prof. Thieblemont is also a key collaborator with the Université Paris Descartes as part of the NFKB, Differentiation and Cancer group (EA7324), and sits on the Scientific Committee of the European School of Haematology.